Elicio Therapeutics, Inc. Common Stock (ELTX)
PHARMACEUTICAL PREPARATIONS
Elicio Therapeutics, Inc. Common Stock (ELTX) is listed on Nasdaq, where it has traded since June 2, 2023.
- Listed On
- Nasdaq
- Listed Since
- June 2, 2023
- Employees
- 33
- Market Cap
- $44M
About Elicio Therapeutics, Inc. Common Stock
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 44 institutions reported holding ELTX, with 3.9 million shares worth $15.3 million in aggregate. The largest reported holder was Knoll Capital Management, with 1.2 million shares worth $4.7 million. Of the 5 largest holders listed below, all 5 added shares during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Knoll Capital Management | 1,211,957 | $5M | Added 92.1% |
| BlackRock | 766,005 | $3M | Added 1413.93% |
| Vanguard | 753,534 | $3M | Added 27.23% |
| Geode Capital Management | 311,354 | $1M | Added 130.35% |
| State Street | 179,420 | $702K | Added 254.44% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ELTX?
Elicio Therapeutics, Inc. Common Stock (ELTX) is listed on Nasdaq, where it has traded since June 2, 2023.
Who are the largest institutional holders of ELTX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ELTX were Knoll Capital Management, BlackRock and Vanguard.
How many institutions own ELTX?
44 institutions reported a position in ELTX for the quarter ended June 30, 2026, worth $15.3 million in total.
Did institutions buy or sell ELTX last quarter?
Of the 5 largest reported holders, all 5 added shares during the quarter. Every reported holder and its change is on the SentiSense ownership page for ELTX.
Every reported institutional holder, plus insider and congressional trades in ELTX, on SentiSense.